CD274 and small cell lung carcinoma: However, clinical trial results—in the SKYSCRAPER-02 trial [7] or this network meta-analysis—have shown no significant benefit to OS or PFS for ES-SCLC patients treated with the Chemo + PD-L1 + TIGIT regimen.